Publicacións nas que colabora con FRANCISCO JOSE HERMIDA PRADO (26)

2024

  1. Combined PIK3CA and SOX2 Gene Amplification Predicts Laryngeal Cancer Risk beyond Histopathological Grading

    International Journal of Molecular Sciences, Vol. 25, Núm. 5

  2. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis

    Journal of translational medicine, Vol. 22, Núm. 1, pp. 135

2023

  1. Driving role of head and neck cancer cell secretome on the invasion of stromal fibroblasts: Mechanistic insights by phosphoproteomics

    Biomedicine and Pharmacotherapy, Vol. 158

  2. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer

    Cancer research, Vol. 83, Núm. 19, pp. 3284-3304

  3. Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Pathobiological functions and clinical implications of annexin dysregulation in human cancers

    Frontiers in Cell and Developmental Biology, Vol. 10

2021

  1. Tumor-infiltrating cd20+ b lymphocytes: Significance and prognostic implications in oral cancer microenvironment

    Cancers, Vol. 13, Núm. 3, pp. 1-16

2020

  1. Expression of E-cadherin and β-catenin in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas

    Acta Otorrinolaringologica Espanola, Vol. 71, Núm. 6, pp. 358-366

  2. Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma

    Oral Oncology, Vol. 110

  3. Lectin-like transcript 1 (LLT1) checkpoint: A novel independent prognostic factor in HPV-negative oropharyngeal squamous cell carcinoma

    Biomedicines, Vol. 8, Núm. 12, pp. 1-14

  4. Prognostic significance of the pluripotency factors NANOG, SOX2, and OCT4 in head and neck squamous cell carcinomas

    Cancers, Vol. 12, Núm. 7, pp. 1-15

2019

  1. Deciphering the molecular basis of melatonin protective effects on breast cells treated with doxorubicin: Twist1 a transcription factor involved in emt and metastasis, a novel target of melatonin

    Cancers, Vol. 11, Núm. 7

  2. SOX2 expression is an independent predictor of oral cancer progression

    Journal of Clinical Medicine, Vol. 8, Núm. 10

  3. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042

    Journal of Clinical Medicine, Vol. 8, Núm. 8

  4. The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma

    Cancers, Vol. 11, Núm. 11

  5. The novel role of SOX2 as an early predictor of cancer risk in patients with laryngeal precancerous lesions

    Cancers, Vol. 11, Núm. 3

  6. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. Analysis of invasive activity of CAF spheroids into three dimensional (3D) collagen matrices

    Methods in Molecular Biology (Humana Press Inc.), pp. 145-154

  2. Distinctive expression and amplification of genes at 11q13 in relation to HPV status with impact on survival in head and neck cancer patients

    Journal of Clinical Medicine, Vol. 7, Núm. 12

  3. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway

    Neoplasia (United States), Vol. 20, Núm. 1, pp. 44-56